Compass Therapeutics Earnings Estimate

CMPX Stock  USD 5.45  0.54  11.00%   
The next projected EPS of Compass Therapeutics is estimated to be -0.1 with future projections ranging from a low of -0.14 to a high of -0.08. Compass Therapeutics' most recent 12-month trailing earnings per share (EPS TTM) is at -0.45. Please be aware that the consensus of earnings estimates for Compass Therapeutics is based on EPS before non-recurring items and includes expenses related to employee stock options.
 
Covid
Compass Therapeutics is projected to generate -0.1 in earnings per share on the 31st of March 2026. Compass Therapeutics earnings estimates show analyst consensus about projected Compass Therapeutics EPS (Earning Per Share). It derives the highest and the lowest estimates based on Compass Therapeutics' historical volatility. Many public companies, such as Compass Therapeutics, manage the perception of their earnings on a regular basis to make sure that analyst estimates are accurate. Future earnings calculations are also an essential input when attempting to value a firm. By analyzing Compass Therapeutics' earnings estimates, investors can diagnose different trends across Compass Therapeutics' analyst sentiment over time as well as compare current estimates against different timeframes. Gross Profit is likely to rise to about 1 M in 2026, whereas Pretax Profit Margin is likely to drop (54.89) in 2026. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Compass Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in inflation.
For more information on how to buy Compass Stock please use our How to Invest in Compass Therapeutics guide.

Compass Therapeutics Earnings Estimation Breakdown

The calculation of Compass Therapeutics' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Compass Therapeutics is estimated to be -0.1 with the future projection ranging from a low of -0.14 to a high of -0.08. Please be aware that this consensus of annual earnings estimates for Compass Therapeutics is based on EPS before non-recurring items and includes expenses related to employee stock options.
Last Reported EPS
0.0
-0.14
Lowest
Expected EPS
-0.1
-0.08
Highest

Compass Therapeutics Earnings Projection Consensus

Suppose the current estimates of Compass Therapeutics' value are higher than the current market price of the Compass Therapeutics stock. In this case, investors may conclude that Compass Therapeutics is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Compass Therapeutics' stock will quickly adjusts to the new information provided by the consensus estimate.
Number of AnalystsHistorical AccuracyLast Reported EPSEstimated EPS for 31st of March 2026Current EPS (TTM)
1571.13%
0.0
-0.1
-0.45

Compass Therapeutics Earnings per Share Projection vs Actual

Actual Earning per Share of Compass Therapeutics refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Compass Therapeutics predict the company's earnings will be in the future. The higher the earnings per share of Compass Therapeutics, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.

Compass Therapeutics Estimated Months Earnings per Share

For an investor who is primarily interested in generating an income out of investing in entities such as Compass Therapeutics, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Compass Therapeutics should always be considered in relation to other companies to make a more educated investment decision.

Compass Quarterly Analyst Estimates and Surprise Metrics

Earnings surprises can significantly impact Compass Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
null
nullnullnullnull
2025-11-05
2025-09-30-0.1432-0.080.063244 
2025-08-11
2025-06-30-0.12-0.14-0.0216 
2025-05-08
2025-03-31-0.11-0.12-0.01
2025-02-28
2024-12-31-0.1-0.11-0.0110 
2024-11-12
2024-09-30-0.11-0.080.0327 
2024-08-12
2024-06-30-0.1-0.10.0
2024-05-13
2024-03-31-0.11-0.080.0327 
2024-03-21
2023-12-31-0.09-0.11-0.0222 
2023-11-09
2023-09-30-0.11-0.080.0327 
2023-08-03
2023-06-30-0.08-0.09-0.0112 
2023-05-04
2023-03-31-0.11-0.060.0545 
2023-03-15
2022-12-31-0.11-0.10.01
2022-11-09
2022-09-30-0.11-0.12-0.01
2022-08-01
2022-06-30-0.08-0.080.0
2022-05-09
2022-03-31-0.11-0.070.0436 
2022-03-18
2021-12-31-0.07-0.21-0.14200 
2021-11-12
2021-09-30-0.12-0.10.0216 
2021-08-16
2021-06-30-1.03-1.07-0.04

About Compass Therapeutics Earnings Estimate

The earnings estimate module is a useful tool to check what professional financial analysts are assuming about the future of Compass Therapeutics earnings. We show available consensus EPS estimates for the upcoming years and quarters. Investors can also examine how these consensus opinions have evolved historically. We show current Compass Therapeutics estimates, future projections, as well as estimates 1, 2, and three years ago. Investors can search for a specific entity to conduct investment planning and build diversified portfolios. Please note, earnings estimates provided by Macroaxis are the average expectations of expert analysts that we track. If a given stock such as Compass Therapeutics fails to match professional earnings estimates, it usually performs purely. Wall Street refers to that as a 'negative surprise.' If a company 'beats' future estimates, it's usually called an 'upside surprise.'
Please read more on our stock advisor page.
Last ReportedProjected for Next Year
Retained Earnings-328.2 M-344.6 M
Retained Earnings Total Equity-245.5 M-257.8 M
Earnings Yield(0.22)(0.23)
Price Earnings Ratio(3.62)(3.81)
Price Earnings To Growth Ratio(0.51)(0.48)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Compass Stock Analysis

When running Compass Therapeutics' price analysis, check to measure Compass Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Compass Therapeutics is operating at the current time. Most of Compass Therapeutics' value examination focuses on studying past and present price action to predict the probability of Compass Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Compass Therapeutics' price. Additionally, you may evaluate how the addition of Compass Therapeutics to your portfolios can decrease your overall portfolio volatility.